OBJECTIVE Optimized production and quality control of ytterbium-175 (Yb-175) labeled pamidronate and alendronate complexes as efficient agents for bone pain palliation has been presented. METHODS Yb-175 labeled pamidronate and alendronate (175Yb-PMD and 175Yb-ALN) complexes were prepared successfully at optimized conditions with acceptable radiochemical purity, stability and significant hydro...

Novel biodegradable Poly (L-lactic acid) (PLLA) microspheres containing ytterbium were designed for intra-tumoral radiotherapy, especially for radioembolization. 175Yb possess both therapeutic beta and diagnostic gamma radiations. In this work, process to make ready radiomicrospheres 175Yb(acac)3-loaded PLLA for more consideration has been investigated. The radiomicrospheres were prepared with ...

Novel biodegradable Poly (L-lactic acid) (PLLA) microspheres containing ytterbium were designed for intra-tumoral radiotherapy, especially for radioembolization. 175Yb possess both therapeutic beta and diagnostic gamma radiations. In this work, process to make ready radiomicrospheres 175Yb(acac)3-loaded PLLA for more consideration has been investigated. The radiomicrospheres were prepared with ...

introduction: bleomycins are dna-binding biomolecules, which can be used as targeted therapy carriers when labeled with particle-emitters such as yb-175. in this work the development of yb-175 bleomycin (175yb-blm) has been reported. methods: yb-175 chloride was obtained by thermal neutron irradiation (3 × 1013 n.cm-2.s-1) of natural yb2o3 samples at various neutron fluxes and irradiation time...

      Bone is the third most common site of metastatic disease. Bone pain is the major source of morbidity associated bone metastasis. Bone-seeking radiopharma- ceuticals have been applied for many years. The ability to simultaneously treat multiple sites of disease with a more probable therapeutic effect in earlier phases of metastatic disease is one of the advantages of radiopharmaceuticals. ...

bone is the third most common site of metastatic disease. bone pain is the major source of morbidity associated bone metastasis. bone-seeking radiopharma- ceuticals have been applied for many years. the ability to simultaneously treat multiple sites of disease with a more probable therapeutic effect in earlier phases of metastatic disease is one of the advantages of radiopharmaceuticals. 175yb ...